optimal staffing for outpatient dermatology clinics is not known, staffing ratios reported by safety-net dermatology clinics are less than ideal, as providers outnumber support staff. Hiring additional nursing staff can help improve clinic productivity and reduce wait times. For example, the increase from 1 nurse per provider to 2 nurses led to a 30% increase in completed visits at 1 university hospital dermatology clinic. 4 In the outpatient dermatology clinic at Parkland Health and Hospital System in Dallas, Texas, the hiring of an additional nurse resulted in a 31% decrease in wait times.
optimal staffing for outpatient dermatology clinics is not known, staffing ratios reported by safety-net dermatology clinics are less than ideal, as providers outnumber support staff. Hiring additional nursing staff can help improve clinic productivity and reduce wait times. For example, the increase from 1 nurse per provider to 2 nurses led to a 30% increase in completed visits at 1 university hospital dermatology clinic. 4 In the outpatient dermatology clinic at Parkland Health and Hospital System in Dallas, Texas, the hiring of an additional nurse resulted in a 31% decrease in wait times. 5 Our survey of safety-net dermatology clinics revealed that they have long wait times for appointment availability, high no-show rates, and are understaffed in regards to medical assistants and nurses. Limitations included small sample size, urban location of all surveyed clinics, and lack of standardized definition of safety-net hospital. The need to characterize gaps in dermatologic care for underserved populations is crucial to allow for improved allocation of the limited financial resources at safety-net hospitals. However, long-term data using tofacitinib monotherapy is still sparse, and we are unaware of the quality of treatment in persons of Asian decent. We report the results of extended tofacitinib monotherapy in adult Korean patients with moderate-to-severe AA. After obtaining approval by the institutional review board, we retrospectively reviewed a prospective database having 32 patients with [30% hair loss who had undergone $4 months of treatment (Table I) . Most (29, 90.6%) patients were refractory to previous treatments, which included oral steroid and cyclosporine. Alopecia severity had been recorded using the Severity of Alopecia Tool (SALT). SALT 50 and SALT 90 were defined by 50% and 90% regrowth, respectively.
Twenty-four patients (75.0%) exhibited [5% hair regrowth: 6 with 5%-50% regrowth (median duration and median total dose of tofacitinib; 7 months and 1960 mg, respectively); 9 with 50%-90% regrowth (9 months and 1820 mg, respectively); and 9 with [90% regrowth (10 months and 2240 mg, respectively). Eight patients showed no response (median duration and median total dose of tofacitinib; 6 months and 2240 mg, respectively). Eighteen patients (56.3%) achieved SALT 50 at a median of 3 (range 2-10) months, and 9 patients (28.1%) acquired SALT 90 at a median of 6 (range 4-11) months. All of them achieved SALT 50 or SALT 90 on a 5-mg twice daily regimen. In 6 patients, the dose was increased (up to 20 mg/day), which accelerated hair regrowth but did not result in SALT 50 during the follow-up period. Two of 18 SALT 50 achievers (11.1%) deteriorated after the initial response but achieved regrowth after 2 months of sustained therapy. There was a statistically significant correlation between percentage of hair regrowth at the last clinical visit and some patient characteristics (Table II) . Men (n ¼ 16; median 26.1%, interquartile range 1.0-67.2) had a significantly lower percentage of hair regrowth than women (n ¼ 16; median 83.8%, interquartile range 40.1-95.2) at their last visits. Patients with alopecia totalis or universalis showed lower percentages of hair regrowth at their last visits, but this difference was not statistically significant.
Most patients (26/32, 81.3%) continued with tofacitinib up to their last follow-up. Five quit because of the lack of efficacy and 1 because of the high cost of treatment. Five patients discontinued tofacitinib after a median of 6 (range 6-7) months because of significant hair regrowth, but hair loss recurred after a median of 2 (range 2-7) months of discontinuing tofacitinib. No serious infections, tuberculosis reactivations, or malignancies occurred during the follow-up period.
In the present study, 56.3% achieved SALT 50 with a 10-mg daily dose of tofacitinib, which is a remarkable finding because most patients had severe and refractory AA of a long duration with their current episode. Previous studies in white patients demonstrated similar efficacies with higher doses of up to 20-25 mg daily or combination treatment with a steroid. 2, 5 This series of patients included only Koreans who used a smaller dose of drug than other series involving white patients. Whether this difference in tofacitinib response is due to ethnic or environmental differences between these populations needs to be investigated in the future.
The duration of the current episode seems to be the most useful clinical indicator to predict treatment response, as repeatedly reported. In addition, we found that duration of disease, age of onset, and sex were also associated with treatment response. Furthermore, longer tofacitinib duration (and not total tofacitinib dose) was associated with a good response, mainly because poor responders were prescribed higher doses within a certain period and discontinued drug use sooner because of lack of efficacy.
All patients regularly received laboratory tests; there were no serious side effects. Five received isoniazid prophylaxis because of latent tuberculosis, and no reactivations were observed.
In summary, tofacitinib monotherapy was effective and well tolerated in Korean patients with moderate-to-severe and refractory AA. The therapeutic effect was obviously not maintained after cessation of treatment; thus, a continuous long-term treatment was required. Further randomized, controlled clinical trials are warranted to confirm adequate dosage, treatment period, and prognostic factors for poor outcomes. prevalence distribution of both sexes resembled a bell-shaped curve, with boys peaking at 12 years of age and girls peaking at 9 years of age (Fig 1) .
To compare the prevalence of AA among different age groups, the patients were divided into 3 broad groups: toddlers (1-5 years of age), children (6-11 years of age), and adolescents (12-17 years of age). Table I shows the prevalence of AA in these age groups.
In 2004, Stern estimated that 9598 total US officebased dermatologists see 47,990,000 dermatology patients per year, with the average dermatologist Age and sex distribution of pediatric alopecia areata patients. Data is presented as the proportion of pediatric patients with alopecia areata of one sex (or both sexes for total) per 1000 pediatric patients of that same sex (or both sexes for total). AA, Alopecia areata. 
